Recent studies have demonstrated dependence on MCL1 expression for the resistance of BRAFV600E mutant melanomas to apoptotic stimuli via the constitutive activation of the RAS/RAF/MEK/ERK signaling pathway. This evidence concerns the gene MCL1 and melanoma.